Jagsonpal Pharmaceuticals Ltd
NSE: JAGSNPHARM BSE: 507789Pharma
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]
₹201
52W: ₹155 — ₹302
PE 30.1 · Book ₹41.2 · +388% vs bookMarket Cap₹1,346 Cr
Stock P/E30.1Price to Earnings
ROCE22.7%Return on Capital
ROE17.3%Return on Equity
Div. Yield1.23%Face Value ₹2
Strengths
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 50.3%
- +Company's working capital requirements have reduced from 24.0 days to 11.0 days
Weaknesses
- −The company has delivered a poor sales growth of 8.85% over past five years.
Shareholding Pattern
Promoters67.89%
FIIs2.44%
DIIs0.22%
Public29.44%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 68.04% | 67.98%▼0.1 | 67.82%▼0.2 | 67.77%▼0.0 | 67.65%▼0.1 | 67.54%▼0.1 | 67.39%▼0.2 | 67.89%▲0.5 |
| FIIs | 1.1% | 2.3%▲1.2 | 2.1%▼0.2 | 2.1% | 2.17%▲0.1 | 2.12%▼0.0 | 2.12% | 2.44%▲0.3 |
| DIIs | 0.84% | 0.11%▼0.7 | 0%▼0.1 | 0% | 0.05%▲0.1 | 0.08%▲0.0 | 0.15%▲0.1 | 0.22%▲0.1 |
| Public | 30.01% | 29.63%▼0.4 | 30.1%▲0.5 | 30.11%▲0.0 | 30.12%▲0.0 | 30.25%▲0.1 | 30.34%▲0.1 | 29.44%▼0.9 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 47.23 | 43.49 | 61.44 | 74.69 | 74.03 | 58.56 | 75.61 | 74.47 | 72.95 | 64.2 |
| Expenses | 43.83 | 40.82 | 51.19 | 58.4 | 58.19 | 49.85 | 61.41 | 58.03 | 56.68 | 53.04 |
| Operating Profit | 3.4 | 2.67 | 10.25 | 16.29 | 15.84 | 8.71 | 14.2 | 16.44 | 16.27 | 11.16 |
| OPM % | 7.2% | 6.14% | 16.68% | 21.81% | 21.4% | 14.87% | 18.78% | 22.08% | 22.3% | 17.38% |
| Net Profit | 3.96 | 3.55 | 5.33 | 11.46 | 31.99 | 6.58 | 10.8 | 12.57 | 10.95 | 8.76 |
| EPS ₹ | 0.6 | 0.54 | 0.81 | 1.73 | 4.82 | 0.99 | 1.62 | 1.89 | 1.64 | 1.31 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹287Cr, up 6.7% YoY. OPM at 20%.
Debt Position
Borrowings at ₹8Cr. Debt-to-equity ratio: 0.03x. Healthy balance sheet.
Institutional Flow
DIIs: 0.22% (-0.60pp change). FIIs: 2.44% (+2.07pp change). Promoters hold 67.89%.
Margin & Efficiency
ROCE improving from 5% (Mar 2015) to 23% (Mar 2026). Working capital days: 11.
Valuation
PE 30.1x with 22.7% ROCE. Price is 388% above book value of ₹41.2. Dividend yield: 1.23%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 7 May - Newspaper Publication regarding dispatch of Letter of Offer of Buy Back to the shareholders of the Company
- Submission Of Letter Of Offer For Buy-Back Upto 16,00,000 Equity Shares 6 May - Jagsonpal launches 16 lakh share buyback at ₹250 each, totaling up to ₹40 crore; opens May 8, 2026.
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 4 May - Earning Call Transcript for meeting held on April 28, 2026
- Announcement under Regulation 30 (LODR)-Newspaper Publication 29 Apr - Newspaper Advertisement- Extract of Audited Financial Results for FY 26
- Announcement under Regulation 30 (LODR)-Newspaper Publication 29 Apr - Submission of Public Announcement pertaining to Buy back of Shares of Company published in the newspaper along with Board and Shareholder Resolution
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse